74 related articles for article (PubMed ID: 19637991)
1. Use of argatroban during multi-organ procurement: pharmacokinetics and sequelae in recipient of transplanted liver.
Schwartz JJ; Hatch JM; Book Z; Lonardo N; Hutson WR; Sorensen JB
Clin Transplant; 2009; 23(5):705-9. PubMed ID: 19637991
[TBL] [Abstract][Full Text] [Related]
2. Responsiveness of the activated partial thromboplastin time and dilute thrombin time to argatroban: Results of an in vitro study.
Scalambrino E; Padovan L; Chantarangkul V; Clerici M; Artoni A; Peyvandi F; Tripodi A
Int J Lab Hematol; 2020 Jun; 42(3):e128-e131. PubMed ID: 32086868
[No Abstract] [Full Text] [Related]
3. Monitoring of the anticoagulants argatroban and lepirudin: a comparison of laboratory methods.
Ivandic B; Zorn M
Clin Appl Thromb Hemost; 2011 Oct; 17(5):549-55. PubMed ID: 20834029
[TBL] [Abstract][Full Text] [Related]
4. Assessment of the potential pharmacokinetic and pharmacodynamic interactions between erythromycin and argatroban.
Tran JQ; Di Cicco RA; Sheth SB; Tucci M; Peng L; Jorkasky DK; Hursting MJ; Benincosa LJ
J Clin Pharmacol; 1999 May; 39(5):513-9. PubMed ID: 10234600
[TBL] [Abstract][Full Text] [Related]
5. Risk factors for new-onset diabetes mellitus in adult liver transplant recipients, an analysis of the Organ Procurement and Transplant Network/United Network for Organ Sharing database.
Kuo HT; Sampaio MS; Ye X; Reddy P; Martin P; Bunnapradist S
Transplantation; 2010 May; 89(9):1134-40. PubMed ID: 20386364
[TBL] [Abstract][Full Text] [Related]
6. Assessment of the cytokine response in liver donors at the time of organ procurement and association with allograft function after orthotopic transplantation.
Palombo JD; Burke PA; Moldawer LL; Forse RA; Lewis WD; Jenkins RL
J Am Coll Surg; 1994 Aug; 179(2):209-19. PubMed ID: 7519108
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of argatroban in primates: evidence on endogenous uptake.
Ahmad S; Yang LH; Ahsan A; Fu K; Iqbal O; Hoppensteadt DA; Lewis BE; Walenga JM; Fareed J
Int Angiol; 2000 Jun; 19(2):126-34. PubMed ID: 10905795
[TBL] [Abstract][Full Text] [Related]
8. Outcome of liver transplantation for recipients with hepatitis B and hepatitis C virus coinfection: analysis of the UNOS data.
Waki K; Sugawara Y; Tamura S; Mieno MN; Yamashiki N; Kadowaki T; Kokudo N
Transplantation; 2011 Oct; 92(7):809-14. PubMed ID: 21832961
[TBL] [Abstract][Full Text] [Related]
9. Impact of the donor risk index on the outcome of hepatitis C virus-positive liver transplant recipients.
Maluf DG; Edwards EB; Stravitz RT; Kauffman HM
Liver Transpl; 2009 Jun; 15(6):592-9. PubMed ID: 19479802
[TBL] [Abstract][Full Text] [Related]
10. Small-molecule direct antithrombins: argatroban.
Fareed J; Jeske WP
Best Pract Res Clin Haematol; 2004 Mar; 17(1):127-38. PubMed ID: 15171962
[TBL] [Abstract][Full Text] [Related]
11. Older donor livers show early severe histological activity, fibrosis, and graft failure after liver transplantation for hepatitis C.
Rayhill SC; Wu YM; Katz DA; Voigt MD; Labrecque DR; Kirby PA; Mitros FA; Kalil RS; Miller RA; Stolpen AH; Schmidt WN
Transplantation; 2007 Aug; 84(3):331-9. PubMed ID: 17700157
[TBL] [Abstract][Full Text] [Related]
12. [Clinical research of donor liver procurement and preparation in liver transplantation].
Lin YX; Zhou J; Lin JH; Wang Y; Zhang GW; Cui ZL; Li XH; Tan YF
Nan Fang Yi Ke Da Xue Xue Bao; 2010 May; 30(5):1012-4. PubMed ID: 20501381
[TBL] [Abstract][Full Text] [Related]
13. Use of liver grafts from donation after cardiac death donors for recipients with hepatitis C virus.
Taner CB; Bulatao IG; Keaveny AP; Willingham DL; Pungpapong S; Perry DK; Rosser BG; Harnois DM; Aranda-Michel J; Nguyen JH
Liver Transpl; 2011 Jun; 17(6):641-9. PubMed ID: 21618684
[TBL] [Abstract][Full Text] [Related]
14. An analysis of liver transplant survival rates from the UNOS registry.
Goh A
Clin Transpl; 2008; ():19-34. PubMed ID: 19711511
[TBL] [Abstract][Full Text] [Related]
15. Coagulation laboratory testing in patients treated with argatroban.
Walenga JM; Fasanella AR; Iqbal O; Hoppensteadt DA; Ahmad S; Wallis DE; Bakhos M
Semin Thromb Hemost; 1999; 25 Suppl 1():61-6. PubMed ID: 10357154
[TBL] [Abstract][Full Text] [Related]
16. Liver transplantation using controlled donation after cardiac death donors: an analysis of a large single-center experience.
Grewal HP; Willingham DL; Nguyen J; Hewitt WR; Taner BC; Cornell D; Rosser BG; Keaveny AP; Aranda-Michel J; Satyanarayana R; Harnois D; Dickson RC; Kramer DJ; Hughes CB
Liver Transpl; 2009 Sep; 15(9):1028-35. PubMed ID: 19718636
[TBL] [Abstract][Full Text] [Related]
17. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia.
Lewis BE; Wallis DE; Leya F; Hursting MJ; Kelton JG;
Arch Intern Med; 2003 Aug 11-25; 163(15):1849-56. PubMed ID: 12912723
[TBL] [Abstract][Full Text] [Related]
18. Anticoagulant activity and pharmacokinetic properties of a sub-cutaneously administered mixed micellar formulation of argatroban in experimental animals.
Berry CN; Lunven C; Lecoffre C; Lainée P; O'Connor SE; André F; Roger B; Garrigou-Gadenne D; Rouchouse A; Roome NO; Vivan N
Thromb Haemost; 2000 Aug; 84(2):278-85. PubMed ID: 10959701
[TBL] [Abstract][Full Text] [Related]
19. HCV+ donors: should they be used for organ transplantation?
Aswad S; Obispo E; Mendez RG; Mendez R
Transplant Proc; 1993 Dec; 25(6):3072-4. PubMed ID: 8266457
[No Abstract] [Full Text] [Related]
20. Prolonged elevation of plasma argatroban in a cardiac transplant patient with a suspected history of heparin-induced thrombocytopenia with thrombosis.
Genzen JR; Fareed J; Hoppensteadt D; Kurup V; Barash P; Coady M; Wu YY
Transfusion; 2010 Apr; 50(4):801-7. PubMed ID: 20003049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
